Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies

DARMSTADT, Germany, June 23, 2022 /PRNewswire/ -- Merck, a leading science and engineering science company, appear that its Life Science concern sector has doubled its high-potent active pharmaceutical ingredients (HPAPI) product capacity with the expansion of its facility in Verona, nearly Madison, Wisconsin, Usa. This new €59 million, lxx,000 square human foot facility, officially opened today, brings fifty new jobs to the expanse.  "At that place is an increasing demand for HPAPIs due to their effectiveness against cancer at lower doses and the tendency towards more targeted therapeutics. Lower-doses of these therapies reduce the negative side effects for patients who are taking on this critical fight," said Dirk Lange, caput of Life Science Services, Life Science, at Merck. "Increasing capacity at our state-of-the-art CDMO facility in Verona, Wisconsin will permit us to meet the need for these key cancer treatment components." Cancer is the second leading cause of death worldwide1. HPAPIs are a disquisitional chemical element of targeted therapies due to their extremely effective jail cell-killing abilities at low doses, resulting in reduced side furnishings for patients. They are used in novel cancer therapies, including antibody drug conjugates (ADCs), which are irresolute the landscape of cancer treatments. Merck has been developing multi-footstep, complex, and highly potent compounds for more than 30 years and continues to exist an industry leader in the development and manufacture of these components. HPAPIs crave specialized handling and manufacturing facilities that protect the safety of employees and their environment. Many potential life-saving treatments never get in to market in part due to the specialized handling requirements. Merck's Verona, Wisconsin site was the second facility in the world to exist SafeBridge®-certified and the visitor continues to run across these rigorous safety and containment requirements necessary to this twenty-four hours. In fact, this expansion positions Merck as ane of the largest single-digit nanogram occupational exposure limit (OEL) CDMO providers in the world. HPAPIs are measured with the virtually potent registering less than 10 nanograms per cubic meter. Unmarried-digit nanogram HPAPIs require highly specialized handling, which is reflected past the OEL designation. In addition to HPAPI production, Merck also has extensive experience developing and manufacturing ADCs. Being the showtime CDMO to industry commercially approved ADC drugs in North America, the company recently launched new technologies to advance ADC therapies. Its unique ChetoSensar™ technology gives new promise to ADCs past alleviating solubility challenges, and Merck's new DOLCORE™ platform significantly reduces development and manufacturing time required, increasing speed-to-market past upwards to a year, ultimately getting needed therapies to patients quicker. With more than 30 years of CDMO feel in the development and manufacturing of HPAPIs, linkers and mAbs, Merck offers significant expertise in both clinical and commercial manufacturing. The visitor also has extensive CDMO experience in viral vector, lipids, LNP and mRNA manufacturing— from pre-clinical to commercial — helping to streamline steps of drug development and production with a single, highly experienced partner. Additionally, BioReliance® contract testing services are integrated into the overall Services offering to farther streamline the evolution path. All Merck press releases are distributed past electronic mail at the same time they become available on the Merck website. Please get to www.merckgroup.com/subscribe to register online, alter your option or discontinue this service. Merck, a leading science and technology company, operates across life science, healthcare and electronics. More sixty,000 employees work to make a positive difference to millions of people'due south lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the about challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of € 19.7 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family unit remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The just exceptions are the U.s.a. and Canada, where the business sectors of Merck operate equally MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. i "Global Cancer Facts & Figures quaternary Edition, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-fourth-edition.pdf Photo - https://mma.prnewswire.com/media/1845670/Verona_expansion_image.jpg

Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies

DARMSTADT, Germany, June 23, 2022 /PRNewswire/ -- Merck, a leading science and applied science company, announced that its Life Science business sector has doubled its loftier-strong active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, well-nigh Madison, Wisconsin, U.s.a.. This new €59 1000000, lxx,000 square pes facility, officially opened today, brings 50 new jobs to the area.

"There is an increasing need for HPAPIs due to their effectiveness confronting cancer at lower doses and the trend towards more targeted therapeutics. Lower-doses of these therapies reduce the negative side effects for patients who are taking on this critical fight," said Dirk Lange, head of Life Science Services, Life Science, at Merck. "Increasing chapters at our state-of-the-art CDMO facility in Verona, Wisconsin will permit us to meet the demand for these primal cancer handling components."

Cancer is the second leading cause of expiry worldwide1. HPAPIs are a critical element of targeted therapies due to their extremely effective cell-killing abilities at low doses, resulting in reduced side furnishings for patients. They are used in novel cancer therapies, including antibiotic drug conjugates (ADCs), which are changing the landscape of cancer treatments.

Merck has been developing multi-step, complex, and highly potent compounds for more than 30 years and continues to be an industry leader in the development and manufacture of these components. HPAPIs require specialized handling and manufacturing facilities that protect the safety of employees and their surroundings. Many potential life-saving treatments never make it to market in part due to the specialized handling requirements. Merck'south Verona, Wisconsin site was the second facility in the world to be SafeBridge®-certified and the company continues to come across these rigorous safety and containment requirements necessary to this day. In fact, this expansion positions Merck as 1 of the largest single-digit nanogram occupational exposure limit (OEL) CDMO providers in the world. HPAPIs are measured with the virtually potent registering less than 10 nanograms per cubic meter. Unmarried-digit nanogram HPAPIs require highly specialized handling, which is reflected past the OEL designation.

In addition to HPAPI production, Merck also has extensive experience developing and manufacturing ADCs. Being the kickoff CDMO to manufacture commercially approved ADC drugs in North America, the company recently launched new technologies to advance ADC therapies. Its unique ChetoSensar™ technology gives new promise to ADCs by alleviating solubility challenges, and Merck's new DOLCORE™ platform significantly reduces development and manufacturing time required, increasing speed-to-market place past up to a yr, ultimately getting needed therapies to patients quicker.

With more than 30 years of CDMO experience in the evolution and manufacturing of HPAPIs, linkers and mAbs, Merck offers pregnant expertise in both clinical and commercial manufacturing. The visitor also has extensive CDMO experience in viral vector, lipids, LNP and mRNA manufacturing— from pre-clinical to commercial — helping to streamline steps of drug evolution and production with a single, highly experienced partner. Additionally, BioReliance® contract testing services are integrated into the overall Services offering to further streamline the development path.

All Merck printing releases are distributed past e-mail at the same fourth dimension they get available on the Merck website. Delight go to www.merckgroup.com/subscribe to register online, change your pick or discontinue this service.

Merck, a leading science and technology company, operates across life scientific discipline, healthcare and electronics. More sixty,000 employees piece of work to make a positive departure to millions of people'south lives every twenty-four hours by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the nigh challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of € 19.7 billion in 66 countries.

Scientific exploration and responsible entrepreneurship accept been key to Merck'due south technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and make. The only exceptions are the United States and Canada, where the business organisation sectors of Merck operate equally MilliporeSigma in life scientific discipline, EMD Serono in healthcare, and EMD Electronics in electronics.

1 "Global Cancer Facts & Figures 4th Edition, https://world wide web.cancer.org/content/dam/cancer-org/enquiry/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-4th-edition.pdf

Photograph - https://mma.prnewswire.com/media/1845670/Verona_expansion_image.jpg